Publications by authors named "Elisabeth Dam"

Claim this Profile
G
Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study.
Iben Spanggaard, Marko Snoj, Andrea Cavalcanti, Céline Bouquet, Gregor Sersa, Elisabeth Dam

Hum Gene Ther Clin Dev· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.
Romina Quercia, Elisabeth Dam, Danielle Perez-Bercoff, François Clavel

J Virol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type.
Saori Matsuoka, Elisabeth Dam, Denise Lecossier, François Clavel, Allan J Hance

Retrovirology· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Elisabeth Dam, Romina Quercia, Bärbel Glass, Diane Descamps, Odile Launay

PLoS Pathog· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
Aurélie Barrail-Tran, Laurence Morand-Joubert, Gwendoline Poizat, Gilles Raguin, Clotilde Le Tiec, Elisabeth Dam

Antimicrob Agents Chemother· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Sofie Mathiesen, Elisabeth Dam, Birgit Roge, Louise Bruun Joergensen, Alex Lund Laursen

Antivir Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Elisabeth Dam, Sophie Lebel-Binay, Séverine Rochas, Laurent Thibaut, Jean-Louis Faudon

Antivir Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.
Laurence Morand-Joubert, Charlotte Charpentier, Gwendoline Poizat, Geneviève Chêne, Elisabeth Dam

Antivir Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors.
Corinne Amiel, Nathalie Desire, Veronique Schneider, Nathalie Delphin, Ester Race, Elisabeth Dam

AIDS· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
Francine Bouchonnet, Elisabeth Dam, Fabrizio Mammano, Vaea de Soultrait, Gaëlle Henneré

J Virol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.
Béatrice Labrosse, Jean-Louis Labernardière, Elisabeth Dam, Virginie Trouplin, Katharina Skrabal

J Virol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis